China Botanic Receives New Patent on its Comprehensive Method to Enhance the Medicinal Value of Schisandra
HARBIN, China, Aug. 28, 2012 /PRNewswire-Asia/ — China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) (“China Botanic” or the “Company”), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines (“TCM”) in China, today announced that the Company has received a notification from the State Intellectual Property Office of the People’s Republic of China (“SIPO”) that China Botanic will be granted a new invention patent on its comprehensive method to enhance the medicinal value of Schisandra. The Company expects to receive the patent certificate by October 2012.
The Company filed its patent application (Patent Application No: 201010119861.3) in February 2010, which was followed by a two-year comprehensive review conducted by the SIPO. Upon grant of the new patent, the Company expects to secure market exclusivity for a period of 20 years.
Research in China suggests that Schisandra is a wild plant with significant medical and health benefits. Schisandra has been found to prevent liver damage and is an effective sedative for treating insomnia and central nervous system depression. Additionally, research indicates Lignin compounds are a good source of powerful anti-oxidants with promising benefits in fighting major conditions, including HIV, cancer and high blood pressure. China Botanic’s comprehensive method to enhance the medicinal value of Schisandra enables the Company to obtain a number of compounds, including lignin, polysaccharides, vitamins and organic acids, out of Schisandra to substantially enhance the efficacy of medicines produced from these compounds and provides a new way to make the best use of water-soluble ingredients and residues from Schisandra.
“Schisandra is one of the important components for our anti-depression and nervous system regulating products. We look forward to receiving the new patent in October, which will further support our research and development of Schisandra, development of Schisandra-based new medicines and strengthen our ability to leverage the potential of Schisandra,” commented Mr. Shaoming Li, Chairman and CEO of China Botanic. “In addition, our continued success in obtaining new patents and our commitment to invest into research, development and talent defines our long-term growth strategy. We believe that in the foreseeable future, our new patent will favorably contribute to our business performance.”
About China Botanic Pharmaceutical Inc.
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines (“TCM”), in the People’s Republic of China. All of the Company’s products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management’s beliefs, assumptions and expectations of the Company’s future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company’s ability to manage expansion of its operations effectively, and other factors detailed in the Company’s annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Company Contact: CCG Investor Relations: China Botanic Pharmaceutical Inc. Mr. Mark Collinson, Partner Ms. Portia Tan, IR Contact Phone: +1-310-954-1343 (Los Angeles) Tel: +86-451-8260-2162 Email: firstname.lastname@example.org Email: email@example.com Website: www.ccgirasia.com
SOURCE China Botanic Pharmaceutical Inc.